

## Pathway Board Meeting

Minutes of the meeting held on 8<sup>th</sup> March 2018

### Members in attendance

|                          |                        |               |                        |
|--------------------------|------------------------|---------------|------------------------|
| Satish Maddineni (Chair) | Pathway Director       | Rose Garvey   | User representative    |
| Mike Thorpe              | User representative    | Noel Clarke   | Consultant Surgeon     |
| Jane Booker              | CNS                    | Daniel Burke  | Consultant Surgeon     |
| Karyee Chow              | Consultant Surgeon     | Mike Scott    | Consultant Pathologist |
| George Yeung             | Consultant Radiologist | Jeremy Oates  | Consultant Surgeon     |
| Tom Waddell              | Consultant Surgeon     | Steve Elliott | GP representative      |
| Stephen Bromage          | Consultant Surgeon     | John Calleary | Consultant Surgeon     |

### In attendance

|               |                          |                 |            |
|---------------|--------------------------|-----------------|------------|
| Rebecca Price | GM Cancer                | Catherine Perry | RESPECT 21 |
| Natasha Smith | User Involvement manager |                 |            |

#### 1. Welcome and introductions

SM welcomed all to the meeting and noted the apologies received.

#### 2. Minutes of the previous meeting and matters arising

The meeting agreed that the minutes were an accurate record and there were no matters arising.

#### 3. Best timed Prostate Pathway update

|                          |  |
|--------------------------|--|
| Discussion summary       | <p>SM presented the final pathway and informed the board of the news that the pathway had been recently presented at a meeting of the Cancer alliances on Feb 8<sup>th</sup>.</p> <p>The Board then had a wide ranging discussion on this proposed pathway, the increased mpMR required, triage and how the sector model may work.</p> <p>Following ratification at this meeting, an application for transformation funding to fund a project to establish project manage the implementation of the pathway will be submitted to the Health &amp; Social Care partnership.</p> |
| Conclusion               | The meeting confirmed that they agree to the principles within the paper and welcomed news from SM regarding the outcome of the funding application.   |
| Actions & responsibility | <b>There were no actions for the board.</b>  |

#### 4. Bladder pathway update

|                          |  |
|--------------------------|--|
| Discussion summary       | <p>JO presented to the board the finalised bladder pathway that had been amended following feedback from the January meeting. He advised that minor wording changes were inserted within the flow diagrams, for clarity of instruction.</p> <p>The Board had a wide ranging discussion on the presentation, during which they reviewed the impact on Urology pathology reporting and specialist pathology support.</p> <p>The board had along discussion on which patients should be discussed at the MDT and the potential for an increased case load often making MDTs lengthy.</p> <p>As a consensus could not be agreed the meeting, the board have agreed to list all patients for MDT and audit 100 patients following to see if any differences to practice were derived from doing so.</p> <p>JO went to outline the patients that need to be seen and managed within the hub service. TE raised the issue of recruitment to clinical trials and how, in the hub, patients would not be excluded from clinical trials.</p> |
| Conclusion               | The meeting confirmed that the board agreed to the principles within the paper.  |
| Actions & responsibility | <b>MDT audit of 100 patients following implementation of the pathway to determine if any differences to practice were noted.</b>   |

#### 5. Audit update

|                          |   |
|--------------------------|---|
| Discussion summary       | DB provided an update on the audit and explained that completion of this was delayed and would be completed in May or June. |
| Conclusion               | The Board noted this report and asked for it to be put the appropriate meeting agenda.                                      |
| Actions & responsibility | <b>JL to add to Board agenda when complete.</b>   |

#### 7. Transformation update

|                          |  |
|--------------------------|--|
| Discussion summary       | DB provided an update on this and confirmed that progress from the last Board has been limited. He confirmed the implementation group continued to meet and he would update the Board accordingly. |
| Conclusion               | The Board noted this report.   |
| Actions & responsibility | <b>There were no actions for the board.</b>  |

#### 8. 100k Genome report

|                          |  |
|--------------------------|--|
| Discussion summary       | The Board noted the tabled report on recruitment to the 100K genome project.                                   |
| Conclusion               | SM as requested for a more detailed breakdown of results for Urology services                                  |
| Actions & responsibility | <b>JL to gather more information from 100K genome team around recruiting site numbers for urology service.</b> |

## **8. Any other business**

**Report on staging urological cancers** - The board noted the tabled report but felt that the data was not less than relevant or useful. Confusion was felt by all as the numbers did not seem to match that of national audits members had previously viewed.

**Action - JL to discuss with SM prior to the next pathway board.**

**HDI trial** – TE outlined a recent trial in Canada that improved PSA control rates following a change in treatment protocols. HE explained the difference between the trial and current provision in GM. However he went to confirm that this would lead to a significant increase in eligibility for treatment.

He confirmed that a business case was being developed to address the difference in provision but this was delayed as a result of awaiting NICE guidance. The board noted this update.

**Mike Thorpe** thanked SM for his leadership and guidance in delivering the National best-timed Prostate pathway project.

## **9. Date and time of next meeting**

**Thursday 8<sup>th</sup> May 2018**

**14.00- 16.00hrs SRFT, Room TBC**